June 23, 2025 07:05 AM EDTUpdated 10:07 AM

Illumina to buy SomaLogic for $350M upfront, pushing further into proteomics

Jared Whitlock

Features Editor

Illumina has agreed to pay $350 million upfront for SomaLogic, the companies announced on Monday, in a deal that underscores the DNA giant’s strategy of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Illumina to buy SomaLogic for $350M upfront, pushing further into proteomics

Jared Whitlock

Features Editor

Sign up to read this article for free.

Acting CDER chief is leaving after almost nine years at FDA

Updated: A puzzling update from Novo Nordisk and new data from Roche at #ADA25

Compass claims Phase 3 win in depression for psilocybin drug, moves closer to FDA filing

FDA's top cell and gene therapy leaders exit agency in ongoing CBER changes

Vertex's diabetes cell therapy allows 10 patients to come off insulin

Digital Twins in GMP Manufacturing: Shaping the Future of CPV with Aizon

Il­lu­mi­na to buy So­ma­Log­ic for $350M up­front, push­ing fur­ther in­to pro­teomics

Jared Whitlock

Features Editor

Sign up to read this article for free.

Act­ing CDER chief is leav­ing af­ter al­most nine years at FDA

Up­dat­ed: A puz­zling up­date from No­vo Nordisk and new da­ta from Roche at #ADA25

Com­pass claims Phase 3 win in de­pres­sion for psilo­cy­bin drug, moves clos­er to FDA fil­ing

FDA's top cell and gene ther­a­py lead­ers ex­it agency in on­go­ing CBER changes

Ver­tex's di­a­betes cell ther­a­py al­lows 10 pa­tients to come off in­sulin

Dig­i­tal Twins in GMP Man­u­fac­tur­ing: Shap­ing the Fu­ture of CPV with Aizon

Illumina to buy SomaLogic for $350M upfront, pushing further into proteomics

Acting CDER chief is leaving after almost nine years at FDA

Updated: A puzzling update from Novo Nordisk and new data from Roche at #ADA25

Compass claims Phase 3 win in depression for psilocybin drug, moves closer to FDA filing

FDA's top cell and gene therapy leaders exit agency in ongoing CBER changes

Vertex's diabetes cell therapy allows 10 patients to come off insulin

Digital Twins in GMP Manufacturing: Shaping the Future of CPV with Aizon